Cross-talk between the androgen receptor and the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer

Current Cancer Drug Targets

Volumn 7, Issue 6, 2007, Pages 591-604

  Wang, Yu ^a   Kreisberg, Jeffrey I ^b   Ghosh, Paramita M ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c VA NORTHERN CALIFORNIA HEALTH CARE SYSTEM   (United States)

Author keywords

Akt; Androgen receptor; Hormone dependence; Prostate cancer

Indexed keywords

ANDROGEN RECEPTOR; BETA CATENIN; CELL CYCLE PROTEIN; FORKHEAD TRANSCRIPTION FACTOR; GLYCOGEN SYNTHASE KINASE 3BETA; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; SOMATOMEDIN C; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXO; WNT PROTEIN;

CANCER INHIBITION; CELL PROLIFERATION; GENETIC TRANSCRIPTION; HUMAN; POINT MUTATION; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; RECEPTOR BINDING; REVIEW; TUMOR GROWTH;

1-PHOSPHATIDYLINOSITOL 3-KINASE; HUMANS; MALE; PHOSPHORYLATION; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR CROSS-TALK; RECEPTORS, ANDROGEN;

EID: 34548397326     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800907781662248     Document Type: Review

References (14)

1. Catalona, W. J. Management of cancer of the prostate. N. Engl. J. Med. 1994, 331, 996-1004.
2. Huggins, C. Two principles in endocrine therapy of cancers: hormone deprival and hormone interference. Cancer Res. 1965, 25, 1163-1167.
3. Huggins, C.; Hodges, C. V. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J. Clin. 1972, 22, 232-240.
4. Melamed, J.; Datta, M. W.; Becich, M. J.; Bosland, M. C.; Dhir, R.; Kajdacsy-Balla, A.; Orenstein, J.; Silver, S.; Fidelia-Lambert, M.; Berman, J.; Resource, C.P.C.T. Prostate Cancer Pathologic Parameters and Clinical Outcome: Results from the Cooperative Prostate Cancer Tissue Resource; National Cancer Institute: Bethesda, MD, 2004.
5. Edwards, J.; Bartlett, J. M. The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 1: Modifications to the androgen receptor. BJU Int. 2005, 95, 1320-1326.
6. Petrylak, D. Therapeutic options in androgen-independent prostate cancer: building on docetaxel. BJU Int. 2005, 96(Suppl 2), 41-46.
7. Brinkmann, A. O.; Blok, L. J.; de Ruiter, P. E.; Doesburg, P.; Steketee, K.; Berrevoets, C. A.; Trapman, J. Mechanisms of androgen receptor activation and function. J. Steroid Biochem. Mol. Biol. 1999, 69, 307-313.
8. Culig, Z.; Klocker, H.; Bartsch, G.; Steiner, H.; Hobisch, A. Androgen receptors in prostate cancer. J. Urol. 2003, 170, 1363-1369.
9. Culig, Z.; Hobisch, A.; Bartsch, G.; Klocker, H. Androgen receptor - an update of mechanisms of action in prostate cancer. Urol. Res. 2000, 28, 211-219.
10. Henshall, S. M.; Quinn, D. I.; Lee, C. S.; Head, D. R.; Golovsky, D.; Brenner, P. C.; Delprado, W.; Stricker, P. D.; Grygiel, J. J.; Sutherland, R. L. Altered expression of androgen receptor in the malignant epithelium and adjacent stroma is associated with early relapse in prostate cancer. Cancer Res. 2001, 61, 423-427.
11. Feldman, B. J.; Feldman, D. The development of androgen-independent prostate cancer. Nat. Rev. Cancer 2001, 1, 34-45.
12. Shi, X. B.; Ma, A. H.; Tepper, C. G.; Xia, L.; Gregg, J. P.; Gandour-Edwards, R.; Mack, P. C.; Kung, H. J.; deVere White, R. W. Molecular alterations associated with LNCaP cell progression to androgen independence. Prostate 2004, 60, 257-271.
13. Graff, J. R.; Konicek, B. W.; McNulty, A. M.; Wang, Z.; Houck, K.; Allen, S.; Paul, J. D.; Hbaiu, A.; Goode, R. G.; Sandusky, G. E.; Vessella, R. L.; Neubauer, B. L. Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression. J. Biol. Chem. 2000, 275, 24500-24505.
14. Murillo, H.; Huang, H.; Schmidt, L. J.; Smith, D. I.; Tindall, D. J. Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state. Endocrinology 2001, 142, 4795-4805.